Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Recruiting

Phase 2

CGB-500 with TofacitinibPhase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Sponsor:

CAGE Bio Inc.

Code:

NCT06810050

Conditions

Atopic Dermatitis (AD)

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

CGB-500 with 0.5% tofacitinib

CGB-500 Ointment with 1% tofacitinib

Vehicle (placebo)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by CAGE Bio Inc. on 2025-02-05.